Recent development in therapeutics for breakthrough pain

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 757-773

  Davis, Mellar P ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Breakthrough; Incident pain; Intranasal; Oral; Pain; Pharmacokinetic; Spinal; Sublingual

Indexed keywords

ALFENTANIL; BUPRENORPHINE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; KETAMINE; LEVOBUPIVACAINE; LEVORPHANOL; LOCAL ANESTHETIC AGENT; METHADONE; MORPHINE; NALOXONE; OPIATE; OXYCODONE; PLACEBO; RADIOISOTOPE; SUFENTANIL; TRAMADOL;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG DOSE TITRATION; DYSGUESIA; FRACTURE; HUMAN; KYPHOPLASTY; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PAIN; PAIN ASSESSMENT; REVIEW; SOMNOLENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, BUCCAL; ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; FENTANYL; HUMANS; NARCOTICS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951845975     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.41     Document Type: Review

References (140)

1. rd Edition. Doyle D, Hanks G, Cherny N, Calman K (Eds). Oxford University Press, Oxford, UK 438-458 (2004).
2. Davies AN, Dickman A, Reid C et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur. J. Pain 13, 331-338 (2009). •• One of the best manuscripts on the subject of breakthrough pain (BTP).
3. Payne R, Coluzzi P, Hart L et al. Longterm safety or oral transmucosal fentanyl citrate for breakthrough cancer pain. J. Pain Symptom Manage. 22 (1), 575-583 (2001). (Pubitemid 32547445)
4. Christie JM, Simmonds M, Patt R et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J. Clin. Oncol. 16 (10), 3238-3245 (1998). (Pubitemid 28481617)
5. Mercadante S, Radbruch L, Caraceni N et al. Episodic (breakthrough) pain. Consensus Conference of an Expert Working Group of the European Association for Palliative Care. Cancer 94, 832-839 (2002). • Important consensus guideline, even though high-grade evidence for managing BTP was not available at the time of publication. (Pubitemid 34132314)
6. Goncalves JJ. The importance of a word: how to translate 'breakthrough'. Palliat. Med. 22 (2), 195 (2008).
7. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J. Pain Symptom Manage. 35 (5), 563-567 (2008).
8. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81, 129-134 (1999). • Russ Portenoy is responsible for placing BTP on the radar screen of clinicians. This is an excellent study on BTP characteristics. (Pubitemid 29199908)
9. Zeppetella G. An assessment of the safety, effcacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage. 20 (4), 253-258 (2000).
10. Caraceni A, Martini C, Zecca E et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med. 18, 177-183 (2004). • This international survey highlights the problem with nomenclature.
11. Montague L, Green CC. Cancer and breakthrough pains impact on a diverse population. Pain Med. 10 (3), 549-561 (2009).
12. Bruera E, Schoeller T, Wenk R et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J. Pain Symptom Manage. 10 (5), 348-355 (1995).
13. Fortner BV, Okon TA, Portenoy RR. A survey of pain-related hospitalizations, emergency department visits, and physician offce visits reported by cancer patients with and without history or breakthrough. J. Pain 3 (1), 38-44 (2002).
14. Davies AN, Vriens J, Kennett A et al. An observational study of oncology patients' utilization of breakthrough pain medication. J. Pain Symptom Manage. 35 (4), 406-411 (2008).
15. Portenoy RK, Hagen NN. Breakthrough pain: defnition, prevalence and characteristics. Pain 45 (1), 273-281 (1990). • Portenoy's original paper on BTP.
16. Mercadante S, Intravaia G, Villari P et al. Intravenous morphine for breakthrough (episodic) pain in an acute palliative care unit: a confrmatory study. J. Pain Symptom Manage. 35 (3), 307-313 (2008).
17. Portenoy RK, Taylor D, Messina J et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain 22, 805-811 (2006). (Pubitemid 44627444)
18. ®). Pain 91, 123-130 (2001). (Pubitemid 32274181)
19. Farrar JT, Clearly J, Rauck R et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trials for treatment of breakthrough pain in cancer patients. J. Natl Cancer Inst. 90 (8), 611-616 (1998). (Pubitemid 28204805)
20. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain 9 (2), 105-121 (2008). •• Important manuscript for anyone reading the pain literature.
21. Farrar JT, Berlin JA, Strom BB. Clinically important changes in acute pain outcome measures: a validation study. J. Pain Symptom Manage. 25 (5), 406-411 (2003).
22. Hagen NA, Stiles C, Nekolaichuk C et al. The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi process and patient think-aloud interview. J. Pain Symptom Manage. 35 (2), 136-152 (2008).
23. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr. Opin. Support. Palliat. Care 3, 1-6 (2009). • Nice review on the features and treatment of BTP.
24. Mercadante S, Villari P, Ferrera P et al. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J. Pain Symptom Manage. 28 (5), 505-510 (2004). (Pubitemid 39422489)
25. Benedetti N, Brock C, Cleeland C et al. NCCN practice guidelines for cancer pain. Oncology 14 (11A), 135-150 (2000).
26. Cherny NI, Portenoy RR. Cancer pain management. Current strategy. Cancer 72 (Suppl. 11), 3393-3415 (1993).
27. Hanks GW, de Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84 (5), 587-593 (2001). •• One manuscript that, if believed, is essential reading. The guidelines are helpful in clinical practice. (Pubitemid 32238990)
28. Cormie PH, Nairn M, Welsh J. Control of pain in adults with cancer: summary of SIGN guidelines. Br. Med. J. 337, 1106-1112 (2008).
29. Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Pain Practice 7 (4), 324-331 (2007). (Pubitemid 350142301)
30. Moksnes K, Fredheim OM, Klepstad P et al. Early pharmacokinetics of nasal fentanyl: is there a signifcant arteriovenous difference? Eur. J. Clin. Pharmacol. 64 (5), 497-502 (2008). • Illustrates the potential problems of interpreting venous pharmacokinetics.
31. Oertel BG, Preibisch C, Wallenhorst T et al. Differential opioid action on sensory and affective cerebral pain processing. Clin. Pharmacol. Ther. 83 (4), 577-588 (2008). (Pubitemid 351417060)
32. Gourlay GK, Cherry DA, Cousins MM. A comparative study of the effcacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25 (3), 297-312 (1986).
33. Weinberg DS, Inturrisi CE, Reidenberg B et al. Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. 44 (3), 335-342 (1988). • Defnitive original study on sublingual opioids.
34. Inturrisi CE, Colburn WA, Kaiko RF et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin. Pharmacol. Ther. 41 (4), 392-401 (1987). (Pubitemid 17058923)
35. Dale O, Hoffer C, Sheffels P et al. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin. Pharmacol. Ther. 72, 536-545 (2002). • Defnitive paper on nasal opioids. (Pubitemid 36237725)
36. Fisher K, Stiles C, Hagen NA et al. Characterization of the early pharmacodynamic profle of oral methadone for cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage. 28 (6), 619-625 (2004). (Pubitemid 39626108)
37. Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J. Palliat. Med. 10 (2), 331-337 (2007). (Pubitemid 46740205)
38. Zhang H, Zhang J, Streisand JJ. Oral mucosal drug delivery. Clin. Pharmacokinet. 41 (9), 661-680 (2002).
39. Reisfeld GM, Wilson GG. Rational use of sublingual opioids in palliative medicine. J. Palliat. Med. 10 (2), 465-475 (2007). •• Important summary on sublingual opioids.
40. Coluzzi PP. Sublingual morphine: effcacy reviewed. J. Pain Symptom Manage. 16, 184-192 (1998).
41. Hagen NA, Fisher K, Victorino C et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J. Palliat. Med. 10 (1), 47-55 (2007). (Pubitemid 46238952)
42. Pannutti F, Rossi AP, Iafelice G et al. Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal and sublingual route. Clinical report and preliminary results on morphine pharmacokinetics. Pharmacol. Res. Commun. 14 (4), 369-380 (1982). (Pubitemid 12007174)
43. McQuay HL, Foley KK. Advances in Pain Research and Therapy. Raven Press, NY, USA 407-412 (1986).
44. Osborne R, Joel S, Trew D et al. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 47 (1), 12-19 (1990). (Pubitemid 20041204)
45. Davis T, Miser AW, Loprinzi CL et al. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Hospice J. 9 (1), 85-91 (1993).
46. Watson NW, Taylor KM, Joel SP et al. A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. J. Pharm. Pharmacol. 48 (12), 1256-1259 (1996).
47. Bell MD, Murray GR, Mishra P et al. Buccal morphine - a new route for analgesia. Lancet 12 (1), 71-73 (1985). (Pubitemid 15189821)
48. Beyssac E, Touaref F, Meyer M et al. Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. 19, 401-405 (1998). (Pubitemid 28393860)
49. Schuh KJ, Walsh SL, Bigelow GE et al. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J. Pharmacol. Exp. Ther. 278 (2), 836-846 (1996).
50. Robbie DD. A trial of sublingual buprenorphine in cancer pain. Br. J. Clin. Pharmacol. 7 (Suppl. 3), S315-S317 (1979).
51. Mendelson J, Upton RA, Everhart ET et al. Bioavailability of sublingual buprenorphine. J. Clin. Pharmacol. 37 (1), 31-37 (1997). (Pubitemid 27131552)
52. Kuhlman JJ Jr, Lalani S, Magluilo J Jr et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J. Anal. Toxicol. 20 (6), 369-378 (1996). (Pubitemid 26327458)
53. Heit HA, Gourlay DD. Buprenorphine: new tricks with an old molecule for pain management. Clin. J. Pain 24 (2), 93-97 (2008).
54. Al-Ghananeem AM, Malkawi AH, Crooks PP. Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech 7 (1), E1-E5 (2006).
55. Kokki H, Rasanen I, Lasalmi M et al. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. Clin. Pharmacokinet. 45 (7), 745-754 (2006). (Pubitemid 43990574)
56. Kokki H, Rasanen I, Reinikainen M et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin. Pharmacokinet. 43 (9), 613-622 (2004). (Pubitemid 38951803)
57. Zeppetella G. Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur. J. Cancer Care (Engl.) 18, 331-337 (2009). • Nice summary of the problems with using oral morphine for BTP.
58. Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J. Pain Symptom Manage. 22 (2), 627-629 (2001). • First paper on the extemporaneous use of parenteral preparations. (Pubitemid 32725801)
59. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat. Med. 15, 243-246 (2001). (Pubitemid 32479462)
60. ®) dosing guidelines. Pain Med. 6 (4), 305-314 (2005). • Important review on the use of sublingual fentanyl.
61. Lee M, Kern SE, Kisicki JC et al. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J. Pain Symptom Manage. 26 (2), 743-747 (2003). (Pubitemid 36952350)
62. Zeppetella G, Ribeiro MM. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst. Rev. 25 (1), CF004311 (2006).
63. Mercandante S, Villari P, Ferrera P et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br. J. Cancer 96, 1828-1833 (2007). • Important study comparing parenteral morphine with transmucosal fentanyl. (Pubitemid 46912022)
64. Bredenberg S, Duberg M, Lennernas B et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur. J. Pharm. Sci. 20, 327-334 (2003). (Pubitemid 37338538)
65. Lennernas B, Hedner R, Holmberg M et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br. J. Clin. Pharmacol. 59 (2), 249-253 (2004). (Pubitemid 40208864)
66. Blick SKA, Wagstaff AJ. Fentanyl buccal tablet in breakthrough pain in opioidtolerant patients with cancer. Drugs 66 (18), 2387-2393 (2006). (Pubitemid 46072453)
67. Darwish M, Kirby M, Jiang JG et al. Bio equivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin. Drug Investig. 28 (1), 1-7 (2008). (Pubitemid 350274395)
68. Darwish M, Tempero K, Kirby M et al. Relative bioavailability of the fentanyl effervescent buccal tablet pg versus oral transmucosal fentanyl citrate 1, 600 pg and dose FEBT 270-1, 300 μg: a single-dose, randomized, open-period study in healthy adult volunteers. Clin. Ther. 28 (5), 715-724 (2006). (Pubitemid 44173055)
69. Darwish M, Kirby M, Robertson P et al. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin. Drug Investig. 27 (9), 605-611 (2007). (Pubitemid 47295719)
70. Slatkin NE, Xie F, Messina J et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol. 5 (7), 327-334 (2007). (Pubitemid 350055013)
71. Portenoy RK, Bennett DS, Rauck R et al. Prevalence characteristics of breakthrough pain in opioid-treated patients with chronic cancer pain. J. Pain 7 (8), 583-591 (2006). (Pubitemid 44137488)
72. Simpson DM, Messina J, Xie F et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 29 (4), 588-601 (2007). (Pubitemid 47016640)
73. Kunz KM, Theisen JA, Schroeder MM. Severe episodic pain: management with sublingual sufentanil. J. Pain Symptom Manage. 8 (4), 189-190 (1993).
74. Chong C, Schug SA, Page-Sharp M et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain. Clin. Drug Invest. 29 (5), 317-324 (2009).
75. Dale O, Hjortkjaer R, Kharasch EE. Nasal administration of opioids for pain management in adults. Acta Anesthesiol Scand. 48, 759-770 (2002). (Pubitemid 34803193)
76. Mercadante S, Arcuri E, Ferrera P et al. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J. Pain Symptom Manage. 30 (5), 485-491 (2005). (Pubitemid 41718968)
77. Wu H, Hu K, Jiang H. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv. 5 (10), 1159-1168 (2008).
78. O'Neil G, Paech N, Wood F. Preliminary clinical use of a patient-control led intranasal analgesia (PCINA) device. Anaesth. Intensive Care 25 (4), 408-412 (1997). (Pubitemid 27389204)
79. Shelley K, Paech MM. The clinical applications of intranasal opioids. Curr. Drug Deliv. 5, 55-58 (2008). • Nice review on the subject of nasal opioids. (Pubitemid 351225634)
80. Jogani V, Jinturkar K, Vyas T, Misra A. Recent patents review on intranasal administration for CNS drug delivery Recent Pat. Drug Deliv. Formul. 2, 25-40 (2008). • Exhaustive review on nasal opioids. (Pubitemid 351546432)
81. Fitzgibbon D, Morgan D, Dockter D et al. Initial pharmacokinetic, safety and effcacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 106, 309-315 (2003). (Pubitemid 37505878)
82. Pavis H, Wilcock A, Edgecombe J et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J. Pain Symptom Manage. 24 (6), 598-602 (2002). (Pubitemid 36120449)
83. Stoker DG, Reber KR, Waltzman LS et al. Analgesic effcacy and safety of morphinechitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med. 9 (1), 3-12 (2008).
84. Christensen KS, Cohen AE, Mermelstein FH et al. The analgesic effcacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model. Pain Med. 107 (6), 2018-2024 (2008).
85. Dale O, Hoffer C, Sheffels P et al. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin. Pharmacol. Ther. 72 (5), 536-545 (2002). (Pubitemid 36237725)
86. Kendall JM, Latter VV. Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects. Clin. Pharmacokinet. 42 (6), 501-513 (2003).
87. Chang SF, Moore L, Chien YY. Pharmacokinetics and bioavailability of hydromorphone: effect of various routes of administration. Pharm. Res. 5 (11), 718-721 (1988). (Pubitemid 19019674)
88. Coda BA, Rudy AC, Archer SM et al. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth. Analg. 97, 117-123 (2003). (Pubitemid 36736548)
89. Takala A, Kaasalainen V, Seppala T et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol. Scand. 41 (2), 309-312 (1997). (Pubitemid 27084661)
90. Zhao Y, Tao T, Wu J et al. Pharmacokinetics of tramadol in rat plasma and cerebrospinal fuid after intranasal administration. J. Pharm. Pharmacol. 60 (9), 1149-1154 (2008).
91. Foster D, Upton R, Christrup L et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann. Pharmacother. 42 (10), 1380-1387 (2008).
92. Christrup LL, Foster D, Popper LD et al. Pharmacokinetics, effcacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, doubledummy, two-way, crossover study. Clin. Ther. 30 (3), 469-481 (2008). (Pubitemid 351483922)
93. Finn J, Wright J, Fong J et al. A randomised crossover trial of patient controlled intranasal for morphine for procedural wound care in adult patients with burns. Burns 30 (3), 262-268 (2004). (Pubitemid 38479907)
94. Striebel HW, Oelmann T, Spies C et al. Patient-controlled intranasal analgesia: a method for noninvasive postoperative pain management. Anesth. Analg. 548-551 (1996). (Pubitemid 26296364)
95. O'Neil G, Paech M, Wood F. Preliminary clinical use of a patient-controlled intranasal analgesia (PCINA) device. Anaesth. Intens. Care 25, 408-412 (1997). (Pubitemid 27389204)
96. Toussaint S, Maidl J, Schwagmeier MD et al. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. Can. J. Anesth. 47 (4), 299-302 (2000).
97. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin. Drug Deliv. 6 (5), 543-552 (2009).
98. th Annual Scientifc Meeting. San Diego, CA, USA, 7-9 May 2009.
99. th Annual Scientifc Meeting. San Diego, CA, USA, 7-9 May 2009.
100. Mercadante S, Radbruch L, Popper L, Korsholm L, Davies A. Effcacy of intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain: an open-label crossover trial. Presented at: 6th Congress of the European Federation of International Association for the Study of Pain Chapters (EFIC). Lisbon, Portugal, 9-12 September 2009.
101. Mercadante S, Radbruch L, Popper L, Korsholm L, Davies A. Ease of use and preference for intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain. Presented at: 6th Congress of the European Federation of International Association for the Study of Pain Chapters (EFIC). Lisbon, Portugal, 9-12 September 2009.
102. Ralley FF. Intranasal opiates: old route for new drugs. Can. J. Anaesth. 36 (5), 491-493 (1989).
103. Helmers JH, Noorduin J, Van Peer A et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can. J. Anaesth. 36 (5), 494-497 (1989). (Pubitemid 19233813)
104. Mathieu N, Cnuddle N, Engelman E et al. Intranasal sufentanil is effective for postoperative analgesia in adults. Can. J. Anaesth. 53 (1), 60-66 (2006). (Pubitemid 43230993)
105. Good P, Jackson K, Brumley D et al. Intranasal sufentanil for cancer-associated breakthrough pain. Palliat. Med. 23, 54-58 (2009).
106. Schwagmeier R, Boerger N, Meissner W et al. Pharmacokinetics of intranasal alfentanil. J. Clin. Anesth. 7 (2), 109-113 (1995).
107. Kroenenberg RR. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J. Pain Palliat. Care Pharmacother. 16 (3), 27-35 (2002).
108. Yanagihara Y, Ohtani M, Kariya S et al. Plasma concentration profles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm. Drug Dispos. 24, 37-43 (2003). (Pubitemid 36124167)
109. Weber F, Wulf J, Gruber M et al. S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthesized children. Paediatr. Anaesth. 14 (12), 983-988 (2004).
110. Carr DB, Goudas LC, Denman WT et al. Safety and effcacy of intranasal ketamine for the treatment of pain in patients with chronic pain: a randomized, double-blind controlled, crossover study. Pain 108 (1-2), 17-27 (2004).
111. Carr DB, Goudas LC, Denman WT et al. Safety and effcacy of intranasal ketamine in a mixed population with chronic pain. Pain 110 (3), 762-764 (2004).
112. Mayell A, Natusch D. Anosmia - a potential complication of intranasal ketamine. Anaesthesia 64 (4), 457-458 (2009).
113. Enting RH, Muchhiano C, Oldenmenger WH et al. The "pain pen" for breakthrough cancer pain: a promising treatment. J. Pain Symptom Manage. 29 (2), 213-217 (2005). (Pubitemid 40279058)
114. Mercadante S, Villari P, Ferrera P et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fxed ratio with the oral daily morphine dose. J. Pain Symptom Manage. 27 (4), 352-359 (2004). (Pubitemid 38410903)
115. Mercadante S, Intravaia G, Villari P et al. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confrmatory study. J. Pain Symptom Manage. 35 (3), 307-313 (2008).
116. Mercadante S, Villari P, Ferrara P et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patient receiving transdermal buprenorphine. J. Pain Symptom Manage. 32 (2), 175-179 (2006). (Pubitemid 44131646)
117. Gonda I. Systematic delivery of drugs to humans via inhalation. J. Aerosol Med. 19 (1), 47-53 (2006).
118. Chrubasik J, Wust H, Friedrich G et al. Absorption and bioavailabilty of nebulized morphine. Br. J. Anaesth. 61 (2), 228-230 (1988).
119. Masood AR, Thomas SS. Systematic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br. J. Clin. Pharmacol. 41 (3), 250-252 (1996).
120. Penson RT, Joel SP, Roberts M et al. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-gluconronide. Br. J. Clin. Pharmacol. 53 (4), 347-354 (2002). (Pubitemid 34415583)
121. Ward ME, Woodhouse A, Mather LL. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin. Pharmacol. Ther. 62 (6), 596-609 (1997). (Pubitemid 28068063)
122. Dershwitz M, Walsh JL, Morishige RJ et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 93 (3), 619-628 (2000).
123. Otulana B, Okikawa J, Linn J et al. Safety pharmacokinetics of inhaled morphine delivered using the AERx system in patients with morderate-to-severe asthma. Int. J. Clin. Pharmacol. Ther. 42 (8), 456-462 (2004). (Pubitemid 39162778)
124. Thipphawong JB, Babul N, Morishige RJ et al. Analgesic effcacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 99, 693-700 (2003). (Pubitemid 37051986)
125. Gonda I, Fiore ET, Johansson K et al. Bolus delivery of morphine solutions with the AERx pain management system (PMS). J. Aerosol Med. 12, 114 (1999).
126. Higgins MJ, Asbury AJ, Brodie MM. Inhaled nebulised fentanyl for postoperative analgesia. Anaesthesia 46 (11), 973-976 (1991).
127. Worsley MH, MacLeod AD, Brodie MJ et al. Inhaled fentanyl as a method of analgesia. Anaesthesia 45 (6), 449-451 (1990).
128. Mather LE, Woodhouse A, Ward ME et al. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br. J. Pharmacol. 46, 37-43 (1998). (Pubitemid 28308422)
129. Liu K, Dayton S, Shi SJ et al. Development of fentanyl citrate AERx system for pulmonary delivery. Presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. New Orleans, LA, USA, 14-18 November 1999.
130. ® multidose dry powder inhaler technology. Drug Dev. Ind. Pharm. 34, 960-965 (2008).
131. Farr SJ, Otulana BB. Pulmonary delivery of opioids as pain therapeutics. Adv. Drug Deliv. Rev. 58, 1076-1088 (2006).
132. Bounes V, Ducasse JL, Bona AM et al. Nebulized morphine for analgesia in an emergency setting. J. Opioid Manage. 6 (1), 23-26 (2009).
133. Pitcairn GR, Lankinen T, Seppala OP et al. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively indendent of the patient's inspiratory effort. J. Aerosol Med. 13 (2), 97-104 (2000). (Pubitemid 30421868)
134. Wu, H, Chen Z, Sun G et al. Intravenous fubiprofen axetil can increase analgesic effect in refractory cancer pain. J. Exp. Clin. Res. 28 (33), 1-4 (2009).
135. Mercadante S, Villari P, Ferrera P et al. Burst ketamine in reserve opioid tolerance in cancer pain. J. Pain Symptom Manage. 25 (4), 302-304 (2003). (Pubitemid 36411784)
136. Mercadante S, Arcuri E, Ferrera P et al. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J. Pain Symptom Manage. 30 (5), 485-491 (2005). (Pubitemid 41718968)
137. Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg. Anesth. 20 (4), 343-346 (1995).
138. Miszczyk L, Tukiendorf A, Gaborek A et al. An evaluation of half-body irradiation in the treatment of widespread, painful metastatic bone disease. Tumori 94 (6), 813-821 (2008).
139. Wardlaw D, Cummings SR, Meirhaeghe JV et al. Effcacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE) : a randomised controlled trial. Lancet 373, 1016-1024 (2009).
140. Ripamonti C, Faganoni E, Campa T et al. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support. Care Cancer 15, 339-342 (2007). (Pubitemid 46295208)